ReviewPeerJ2025
The expression of metastasis associated protein 2 in normal development and cancers: mechanism and clinical significance.
Review in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MTA2: Decoding pathogenic mechanisms, clinical implications and therapeutic frontiers across disease landscapes (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis-associated protein 2 (MTA2), a master transcriptional regulator, through multiple target genes and interacting proteins, has been demonstrated to play a vital role in the regulation of proliferation, replication, apoptosis, autophagy, DNA damage repair, preimplantation, embryonic development and immune cell differentiation. Despite extensive research, the physiological role and pathogenic mechanisms of MTA2 remain poorly understood. Here, we mainly review in the current research the status of MTA2 and its implications in normal development and various tumor biology. Accumulating evidence suggests that MTA2 is frequently amplify in several types of cancers, closely associates with tumor cells migration and invasion, relates to the malignant characteristics and poor prognosis, which therefore has been considered as playing tumor oncogenic roles. Substantial evidence indicates that MTA2 functions by modulating downstream targets including cell growth, invasion as well as angiogenesis related genes. Confusingly, the proliferation effect of MTA2 remains elusive and even conflicting in the development of several solid tumors. Furthermore, we discuss the upstream regulation of MTA2 by transcription factors, microRNAs and lncRNAs in specific physiology and pathology conditions, which results in the abnormal MTA2 expression in various aspects of cancer. In this context, we summarize linked function of MTA2 directly to oncogenesis and might provide a significant avenue for the treatment of diseases. We hope that this review will help tumor molecular biologists further understand the molecular mechanism of MTA2 in normal development and cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.